Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients

Authors: Juana Gómez-Benito, Georgina Guilera, Óscar Pino, Emilio Rojo, Rafael Tabarés-Seisdedos, Gemma Safont, Anabel Martínez-Arán, Manuel Franco, Manuel J Cuesta, Benedicto Crespo-Facorro, Miguel Bernardo, Eduard Vieta, Scot E Purdon, Francisco Mesa, Javier Rejas, the Spanish Working Group in Cognitive Function

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

The Screen for Cognitive Impairment in Psychiatry (SCIP) is a simple and easy to administer scale developed for screening cognitive deficits. This study presents the diagnostic-specific standardization data for this scale in a sample of schizophrenia and bipolar I disorder patients.

Methods

Patients between 18 and 55 years who are in a stable phase of the disease, diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder were enrolled in this study.

Results

The SCIP-S was administered to 514 patients (57.9% male), divided into two age groups (18–39 and 40–55 years) and two educational level groups (less than and secondary or higher education). The performance of the patients on the SCIP-S is described and the transformed scores for each SCIP-S subtest, as well as the total score on the instrument, are presented as a percentile, z-score, T-scores, and IQ quotient.

Conclusions

We present the first jointly developed benchmarks for a cognitive screening test exploring functional psychosis (schizophrenia and bipolar disorder), which provide increased information about patient’s cognitive abilities. Having guidelines for interpreting SCIP-S scores represents a step forward in the clinical utility of this instrument and adds valuable information for its use.
Literature
1.
Jakobsen KD, Hansen T, Werge T: Diagnostic stability among chronic patients with functional psychoses: an epidemiological and clinical study. BMC Psychiatry. 2007, 7: 41-10.1186/1471-244X-7-41.CrossRefPubMedPubMedCentral
2.
Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998, 12: 426-445.CrossRefPubMed
3.
Krabbendam L, Arts B, van Os J, Aleman A: Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005, 80: 137-149. 10.1016/j.schres.2005.08.004.CrossRefPubMed
4.
Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos R, Balanzá-Martínez V, Salazar-Fraile J, Selva-Vera G, Vieta E: Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom. 2006, 75: 72-84. 10.1159/000090891.CrossRefPubMed
5.
Cuesta MJ, Peralta V, Zarzuela A: Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis. Schizophr Res. 2007, 95: 39-47. 10.1016/j.schres.2007.06.021.CrossRefPubMed
6.
Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, Bromet E: Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009, 35: 1022-1029. 10.1093/schbul/sbn044.CrossRefPubMed
7.
Francey SM, Jackson HJ, Phillips LJ, Wood SJ, Yung AR, McGorry PD: Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophr Res. 2005, 79: 127-136. 10.1016/j.schres.2005.06.023.CrossRefPubMed
8.
Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P: Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991, 48: 618-624. 10.1001/archpsyc.1991.01810310036007.CrossRefPubMed
9.
Tamminga CA, Stan AD, Wagner AD: The hippocampal formation in schizophrenia. Am J Psychiatry. 2010, 167: 1178-1193. 10.1176/appi.ajp.2010.09081187.CrossRefPubMed
10.
Studentkowski G, Scheele D, Calabrese P, Balkau F, Höffler J, Aubel T, Edel MA, Juckel G, Assion HJ: Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia. Eur J Med Res. 2010, 15: 70-78.PubMedPubMedCentral
11.
Greenwood KE, Morris R, Sigmundsson T, Landau S, Wykes T: Executive functioning in schizophrenia and the relationship with symptom profile and chronicity. J Int Neuropsychol Soc. 2008, 14: 782-792.CrossRefPubMed
12.
Basso MR, Lowery N, Ghormley C, Ward T, Purdie R, Neel J, Combs DR, Bornstein RA: Neuropsychological impairment and psychosis in mania. J Clin Exp Neuropsychol. 2009, 31: 523-532. 10.1080/13803390802304516.CrossRefPubMed
13.
Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH: Verbal fluency as a possible predictor for psychosis. Eur Psychiatry. 2010, 25: 105-110.CrossRefPubMed
14.
Bonner-Jackson A, Grossman LS, Harrow M, Rosen C: Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge. Compr Psychiatry. 2010, 51: 471-479. 10.1016/j.comppsych.2010.02.005.CrossRefPubMedPubMedCentral
15.
González-Blanch C, Rodríguez-Sánchez JM, Pérez-Iglesias R, Pardo-García G, Martínez-García O, Vázquez-Barquero JL, Crespo-Facorro B: First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing. Schizophr Res. 2010, 119: 18-26. 10.1016/j.schres.2010.02.1072.CrossRefPubMed
16.
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996, 153: 321-330.CrossRefPubMed
17.
Harvey PD, Sharma T: Understanding and treating cognition in schizophrenia: A clinician’s handbook. 2002, London: Dunitz
18.
Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martinez-Aran A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gómez-Beneyto M, Vieta E: Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord. 2008, 109: 286-299. 10.1016/j.jad.2007.12.234.CrossRefPubMed
19.
Simonsen C, Sundet K, Vaskinn A, Ueland T, Romm KL, Hellvin T, Melle I, Friis S, Andreassen OA: Psychosocial function in schizophrenia and bipolar disorder: relationship to neurocognition and clinical symptoms. J Int Neuropsychol Soc. 2010, 28: 1-13.
20.
Green MF, Nuechterlein KH: The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004, 72: 1-3. 10.1016/j.schres.2004.09.006.CrossRefPubMed
21.
Kern RS, Green MF, Nuechterlein KH, Deng BH: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res. 2004, 72: 11-19. 10.1016/j.schres.2004.09.004.CrossRefPubMed
22.
Carter CS, Barch DM: Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007, 33: 1131-1137. 10.1093/schbul/sbm081.CrossRefPubMedPubMedCentral
23.
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007, 33: 1120-1130. 10.1093/schbul/sbm083.CrossRefPubMedPubMedCentral
24.
Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR: The MATRICS consensus cognitive battery, part 2: co-norming and standardization. Am J Psychiatry. 2008, 165: 214-220. 10.1176/appi.ajp.2007.07010043.CrossRefPubMed
25.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR: The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008, 165: 203-213. 10.1176/appi.ajp.2007.07010042.CrossRefPubMed
26.
Kiernan RJ, Mueller J, Langston JW, Van Dyke C: The neurobehavioral cognitive status examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med. 1987, 107: 481-485. 10.7326/0003-4819-107-4-481.CrossRefPubMed
27.
Randolph C, Tierney MC, Mohr E, Chase TN: The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998, 20: 310-319. 10.1076/jcen.20.3.310.823.CrossRefPubMed
28.
Woodcock RW, McGrew KS, Mather N: Woodcock-Johnson III tests of cognitive abilities. 2001, Itasca, IL: Riverside
29.
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L: The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004, 68: 283-297. 10.1016/j.schres.2003.09.011.CrossRefPubMed
30.
Velligan DI, DiCocco M, Bow-Thomas CC, Cadle C, Glahn DC, Miller AL, Biggs MM, Shores-Wilson K, McKenzie CA, Crismon ML: A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res. 2004, 71: 273-283. 10.1016/j.schres.2004.02.027.CrossRefPubMed
31.
Purdon SE: The Screen for Cognitive Impairment in Psychiatry (SCIP): Instructions and three alternate forms. 2005, PNL Inc, Edmonton: Alberta
32.
Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM: A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011, 37: 538-545. 10.1093/schbul/sbp095.CrossRefPubMed
33.
Guilera G, Pino O, Gómez-Benito J, Rojo JE, Vieta E, Tabarés-Seisdedos R, Segarra N, Martínez-Arán A, Franco M, Cuesta MJ, Crespo-Facorro B, Bernardo M, Purdon SE, Díez T, Rejas J, on behalf of the Spanish Working Group in Cognitive Function: Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health Qual Life Outcomes. 2009, 7: 28-10.1186/1477-7525-7-28.CrossRefPubMedPubMedCentral
34.
Pino O, Guilera G, Rojo E, Gómez-Benito J, Bernardo M, Crespo-Facorro B, Cuesta MJ, Franco M, Martinez-Arán A, Segarra N, Tabarés-Seisdedos R, Vieta E, Purdon SE, Díez T, Rejas J, the Spanish Working Group in Cognitive Function: Spanish version of the screen for cognitive impairment in psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophr Res. 2008, 99: 139-148. 10.1016/j.schres.2007.09.012.CrossRefPubMed
35.
Rojo E, Pino O, Guilera G, Gómez-Benito J, Purdon SE, Crespo-Facorro B, Cuesta MJ, Franco M, Martínez-Arán A, Segarra N, Tabarés-Seisdedos R, Vieta E, Bernardo M, Mesa F, Rejas J, on behalf of the Spanish Working Group in Cognitive Function: Neurocognitive diagnosis and cut-off scores of the screen for cognitive impairment in psychiatry (SCIP-S). Schizophr Res. 2010, 116: 243-251. 10.1016/j.schres.2009.08.005.CrossRefPubMed
36.
Pino O, Guilera G, Gómez J, Rojo JE, Vallejo J, Purdon SE: Escala breve para evaluar el deterioro cognitivo en pacientes psiquiátricos. Psicothema. 2006, 18: 447-452.PubMed
37.
Anastasi A, Urbina S: Psychological testing. 1997, NJ: Prentice Hall, 7
38.
Kendall PC, Marrs-Garcia A, Nath SR, Sheldrick RC: Normative comparisons for the evaluation of clinical significance. J Consult Clin Psychol. 1999, 67: 285-299.CrossRefPubMed
39.
Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW: Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophren Res. 2004, 70: 175-186. 10.1016/j.schres.2003.10.009.CrossRef
40.
Iverson GL, Brooks BL, Haley GM: Interpretation of the RBANS in inpatient psychiatry: clinical normative data and prevalence of low scores for patients with schizophrenia. Appl Neuropsychol. 2009, 16: 31-41. 10.1080/09084280802644128.CrossRefPubMed
41.
American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Text Revision (DSM-IV TR). 2000, Washington DC: APA, 4CrossRef
42.
Kay SR, Opler LA, Fiszbein A: The positive and negative syndrome scale (PANSS). Rat Man Soc Behav Sci Doc. 1986, 17: 28-29.
43.
Peralta V, Cuesta MJ: Escala del síndrome positivo y negativo en la esquizofrenia (PANSS), Manual de puntuación. 2004, Madrid: Janssen
44.
45.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978, 133: 429-435. 10.1192/bjp.133.5.429.CrossRefPubMed
46.
47.
Keefe RS, Fenton WS: How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr Bull. 2007, 33: 912-920. 10.1093/schbul/sbm046.CrossRefPubMedPubMedCentral
48.
Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ, Malec JF: Mayo's Older Americans normative studies: Age- and IQ-adjusted norms for the auditory verbal learning test and the visual spatial learning test. Clin Neuropsychol. 2005, 19: 464-523. 10.1080/13854040590945193.CrossRefPubMed
49.
Choca JP, Krueger KR, de la Torre GG, Corral S, Garside D: Demographic adjustments for the Spanish version of the WAIS-III. Arch Clin Neuropsychol. 2009, 24: 619-629. 10.1093/arclin/acp049.CrossRefPubMed
50.
van Haren NE, Hulshoff Pol HE, Schnack HE, Cahn W, Brans R, Carati I, Rais M, Kahn RS: Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008, 63: 106-113. 10.1016/j.biopsych.2007.01.004.CrossRefPubMed
51.
Brans RG, Kahn RS, Schnack HG, van Baal GC, Posthuma D, van Haren NE, Lepage C, Lerch JP, Collins DL, Evans AC, Boomsma DI, Hulshoff Pol HE: Brain plasticity and intellectual ability are influenced by shared genes. J Neurosci. 2010, 30: 5519-5524. 10.1523/JNEUROSCI.5841-09.2010.CrossRefPubMed
52.
Schofield PW, Marder K, Dooneief G, Jacobs DM, Sano M, Stern Y: Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry. 1997, 154: 609-615.CrossRefPubMed
53.
Hohman TJ, Beason-Held LL, Lamar M, Resnick SM: Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011, 25: 125-130.CrossRefPubMedPubMedCentral
54.
Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA: Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006, 59: 863-871. 10.1016/j.biopsych.2005.09.005.CrossRefPubMed
55.
Woodberry KA, Seidman LJ, Giuliano AJ, Verdi MB, Cook WL, McFarlane WR: Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr Res. 2010, 123: 188-198. 10.1016/j.schres.2010.06.021.CrossRefPubMedPubMedCentral
56.
Zanelli J, Reichenberg A, Morgan K, Fearon P, Kravariti E, Dazzan P, Morgan C, Zanelli C, Demjaha A, Jones PB, Doody GA, Kapur S, Murray RM: Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry. 2010, 167: 78-85. 10.1176/appi.ajp.2009.09010118.CrossRefPubMed
57.
Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Færden A, Jo´nsdo´ttir H, Ringen PA, Opjordsmoen S, Melle I, Friis S, Andreassen OA: Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 2011, 37: 73-83. 10.1093/schbul/sbp034.CrossRefPubMed
Metadata
Title
The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients
Authors
Juana Gómez-Benito
Georgina Guilera
Óscar Pino
Emilio Rojo
Rafael Tabarés-Seisdedos
Gemma Safont
Anabel Martínez-Arán
Manuel Franco
Manuel J Cuesta
Benedicto Crespo-Facorro
Miguel Bernardo
Eduard Vieta
Scot E Purdon
Francisco Mesa
Javier Rejas
the Spanish Working Group in Cognitive Function
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-127

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Research article

Major depression epidemiology from a diathesis-stress conceptualization

Research article

The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study

Research article

Temperamental factors predict long-term modifications of eating disorders after treatment

Research article

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

Review

Perplexities of treatment resistence in eating disorders

Research article

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia